Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Treatment of Abnormal Uterine Bleeding Post-Coital with Uterine Fibroids

Medical Management

  • The American College of Radiology recommends NSAIDs and estrogen-progestin oral contraceptive pills as first-line medical treatments for reducing bleeding symptoms associated with uterine fibroids 1, 2
  • Tranexamic acid is an effective nonhormonal alternative that can reduce bleeding symptoms in patients with fibroids who cannot use hormonal options 2, 3
  • Progestin-containing intrauterine devices (IUDs) can effectively reduce bleeding symptoms and should be considered for long-term management 4
  • GnRH agonists and oral GnRH antagonists are effective second-line options that reduce bleeding symptoms and significantly reduce fibroid volume by 18-30% 2, 5
  • Combination treatment with low doses of estrogen and progestin can mitigate hypoestrogenic side effects and is FDA-approved for fibroid-related heavy menstrual bleeding 2, 4

Surgical Management

  • Hysteroscopic myomectomy is the procedure of choice for pedunculated submucosal uterine fibroids <5 cm, offering shorter hospitalization and faster recovery compared to laparoscopic or open myomectomy 2, 5
  • Hysterectomy provides definitive resolution of all fibroid-related symptoms and remains the most common treatment for uterine fibroids, accounting for three-quarters of fibroid treatments in the United States 2, 5

Minimally Invasive Alternatives

  • Uterine Artery Embolization (UAE) is effective for patients with adenomyosis and fibroids who desire uterus-preserving therapy, improving symptom scores and quality of life for up to 7 years follow-up 1, 5
  • MR-guided Focused Ultrasound (MRgFUS) can be considered, though it has a higher reintervention rate (30%) compared to UAE (13%) 3, 4

Important Considerations

  • The reintervention rate after UAE is approximately 7% for persistent symptoms 1, 5
  • Progesterone receptor modulators show promise but have limited availability in the US due to concerns about hepatotoxicity 2, 4

REFERENCES